CPH · STRAP.CO
Strategic Partners A/S
DKK 635.00-DKK 15.00 (-2.31%)
Strategic Partners A/S’s quoted price sits in the lower half of its reported 52-week range, 32.88% below the high.
Loading market information…
OTC · VOQP · USD
Stock price, earnings
Quote as of Aug 4, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
VioQuest Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow VioQuest Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
VioQuest Pharmaceuticals, Inc. is a biopharmaceutical entity that concentrates on obtaining, developing, and marketing drug therapies in clinical stages, specifically targeting oncology and infectious diseases. Its primary product, Xyfid, is currently being advanced for both the management and prevention of hand-foot syndrome. The company's pipeline also features VQD-002, a nucleoside analog presently in Phase I clinical trials for cancer treatment. Another key compound is Lenocta, a small molecule designed to inhibit various protein tyrosine phosphatases, which is progressing through Phase IIa clinical studies for indications like melanoma, renal cell carcinoma, and other solid tumors. Beyond its therapeutic drug development, VioQuest Pharmaceuticals offers chiral products, specialized technology, and bespoke synthesis development services. These services are provided to pharmaceutical and fine chemical companies at different stages of their product lifecycles. The firm was established in 2000 and operates from its corporate headquarters in Basking Ridge, New Jersey.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
DKK 635.00-DKK 15.00 (-2.31%)
Strategic Partners A/S’s quoted price sits in the lower half of its reported 52-week range, 32.88% below the high.
$0.03+$0.03 (+26,900.0%)
Vaxxinity, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.5% below the high.
$0.00+$0.00 (0.0%)
PaxMedica, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 96.5% below the high.
$0.00$0.00 (0.0%)
Scopus BioPharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.0% below the high.
$0.00$0.00 (0.0%)
Regenicin, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.99% below the high.
$0.00$0.00 (0.0%)
Aeolus Pharmaceuticals, Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00-$0.00 (0.0%)
Q BioMed Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.6% below the high.
$0.00$0.00 (0.0%)
NanoLogix, Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.0% below the high.
